TrialFrontiers of medicine2023

Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial.

Yifan Chang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.